Intercytex to use BioLife's HypoThermosol in cellular therapy trials

08/26/2013 | Pharmaceutical Business Review Online

BioLife Solutions' cell and tissue storage/shipping medium HypoThermosol will be used in ongoing clinical studies of Intercytex's cell-based treatment ICX-RHY-013 in patients with burn injuries and recessive dystrophic epidermolysis bullosa in the U.S. and Europe. HypoThermosol will be used as the delivery solution for therapeutic cells and as the placebo in the control group.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC